These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9193315)

  • 21. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents.
    Baulac M; Nordmann JP; Lanoé Y
    Lancet; 1998 Aug; 352(9127):546. PubMed ID: 9716066
    [No Abstract]   [Full Text] [Related]  

  • 23. [Vigabatrin and alterations of the visual field].
    Argumosa A; Herranz JL; Arteaga R; Barrasa J; Calles L; Armijo J
    Rev Neurol; 1999 Apr 16-30; 28(8):741-5. PubMed ID: 10363313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 25. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 27. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vigabatrin and visual fields defects].
    Jensen K
    Ugeskr Laeger; 2001 Jan; 163(2):184. PubMed ID: 11379251
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
    Riise P; Fledelius HC; Rogvi-Hansen Bà
    Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guideline may help in prescribing vigabatrin.
    Appleton RE
    BMJ; 1998 Nov; 317(7168):1322. PubMed ID: 9804738
    [No Abstract]   [Full Text] [Related]  

  • 34. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.
    Krauss GL; Johnson MA; Miller NR
    Neurology; 1998 Mar; 50(3):614-8. PubMed ID: 9521245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversibility of vigabratin-induced visual-field defect.
    Versino M; Veggiotti P
    Lancet; 1999 Aug; 354(9177):486. PubMed ID: 10465180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Visual field defects due to antiepileptic drugs].
    Stefan H; Bernatik J; Knorr J
    Nervenarzt; 1999 Jun; 70(6):552-5. PubMed ID: 10412701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study is needed of visual field defects associated with any long term antiepileptic drug.
    Rao GP; Fat FA; Kyle G; Leach JP; Chadwick DW; Batterbury M
    BMJ; 1998 Jul; 317(7152):206. PubMed ID: 9665915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.